Key result
Coronary artery calcium of zero in individuals recommended for lipid-lowering therapy was associated with a low 10-year cardiovascular mortality rate of 3.0% compared to 9.0% for any calcium.
Why the study?
Does coronary artery calcium testing improve risk stratification for lipid-lowering therapy compared to standard 2016 ESC recommendations?
Cohort (n=5,602)
Does coronary artery calcium testing improve risk stratification for lipid-lowering therapy compared to standard 2016 ESC recommendations?
Answers are grounded in this paper and cite their sources.
The absence of coronary artery calcium identifies individuals with a low incidence of cardiovascular mortality, suggesting that a significant proportion of patients recommended for lipid-lowering therapy by ESC guidelines could be reclassified to a lower risk group.
AIMS: The European Society of Cardiology (ESC) guideline on cardiovascular risk assessment considers coronary artery calcium a class B indication for risk assessment. We evaluated the degree to which coronary artery calcium can change the recommendation for individuals based on a change in estimated risk. METHODS AND RESULTS: We stratified 5602 MESA participants according to the ESC recommendation as: no lipid-lowering treatment recommended ( N = 2228), consider lipid-lowering treatment if uncontrolled ( N = 1686), or lipid-lowering treatment recommended ( N = 1688). We evaluated the ability of coronary artery calcium to reclassify cardiovascular risk. Among the selected sample, 54% had coronary artery calcium of zero, 25% had coronary artery calcium of 1-100 and 21% had coronary artery calcium greater than 100. In the lipid-lowering treatment recommended group 31% had coronary artery calcium of zero, while in the lipid-lowering treatment if uncontrolled group about 50% had coronary artery calcium of zero. The cardiovascular mortality rate was 1.7%/10 years in the lipid-lowering treatment if uncontrolled, and 7.0%/10 years in the lipid-lowering treatment recommended group. The absence of coronary artery calcium was associated with 1.4%/10 years in the lipid-lowering treatment if uncontrolled group and 3.0%/10 years in the lipid-lowering treatment recommended group. Compared with coronary artery calcium of zero, any coronary artery calcium was associated with significantly higher cardiovascular mortality in the lipid-lowering treatment recommended group (9.0%/10 years), whereas only coronary artery calcium greater than 100 was significantly associated with a higher cardiovascular mortality in the lipid-lowering treatment if uncontrolled group (3.2%/10 years). CONCLUSION: The absence of coronary artery calcium is associated with a low incidence of cardiovascular mortality or coronary heart disease events even in individuals in whom lipid-lowering therapy is recommended. A significant proportion of individuals deemed to be candidates for lipid-lowering therapy might be reclassified to a lower risk group with the use of coronary artery calcium.
No takes yet. Share an insight, caveat, or question.
Bittencourt et al. (2018) conducted a cohort in Cardiovascular risk (n=5,602). Coronary artery calcium testing vs. Coronary artery calcium of zero was evaluated on Cardiovascular mortality. Coronary artery calcium of zero in individuals recommended for lipid-lowering therapy was associated with a low 10-year cardiovascular mortality rate of 3.0% compared to 9.0% for any calcium.
Synapse has enriched 10 related papers. Consider them for comparative context: